Skip to main
AYTU
AYTU logo

Aytu BioScience (AYTU) Stock Forecast & Price Target

Aytu BioScience (AYTU) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Aytu BioPharma Inc. possesses an attractive current valuation supported by a net present value (NPV) analysis, indicating significant upside potential from its current share price. Additionally, the company is anticipating a strong market entry for its new EXXUA drug, targeting major depressive disorder (MDD) in Q4 2025, which is expected to serve as a key catalyst for future stock performance. The successful clinical outcomes of EXXUA, including its ability to improve depression symptoms while minimizing common side effects, further enhance the company's growth prospects in a competitive therapeutic landscape.

Bears say

Aytu BioPharma's stock is currently trading significantly below projections of future sales, indicating potential valuation concerns. Despite the noted growth prospects and the significant unmet needs in the antidepressant market, the company faces high risks that may overshadow these opportunities. Additionally, the reliance on third-party sales for its prescription pharmaceutical products raises uncertainties regarding revenue stability in a competitive landscape.

Aytu BioScience (AYTU) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aytu BioScience and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aytu BioScience (AYTU) Forecast

Analysts have given Aytu BioScience (AYTU) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Aytu BioScience (AYTU) has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aytu BioScience (AYTU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.